Since the outlook of the weight-loss medicine lorcaserin is thronged open into question mark after a Food and Drug Administration Panel suggested against its endorsement on Thursday, shares of Arena Pharmaceuticals Inc. jumped to the lowest level ever on Friday.

The San Diego group is now facing the challenging task of dealing with questions regarding lorcaserin's security that includes a probable cancer peril that wasn't identified widely until this week which is for a drug that has modest efficiency and might be utilized in millions of comparatively healthy people for a extended period of time.

According to Oppenheimer analyst Bret Holley they jostle to view how Arena will alleviate these matters devoid of long-term preclinical/clinical data. Company representatives have turned down to conjecture on whether added experiments might be required.

The board’s unenthusiastic suggestion is a stern hindrance for Arena that has no other products of note, in addition to the other companies with corpulence drugs as it advices the elevated bar that the government agency has for these medications. The wider FDA is anticipated to create its verdict by Oct. 22.